| 2.53 0.16 (6.75%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.88 | 1-year : | 6.36 |
| Resists | First : | 4.18 | Second : | 5.44 |
| Pivot price | 2.69  |
|||
| Supports | First : | 2.14 | Second : | 1.78 |
| MAs | MA(5) : | 2.34 |
MA(20) : | 2.83 |
| MA(100) : | 3.83 |
MA(250) : | 11.28 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 18.9 |
D(3) : | 11.1 |
| RSI | RSI(14): 40.6 |
|||
| 52-week | High : | 68.08 | Low : | 2.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ADTX ] has closed above bottom band by 39.2%. Bollinger Bands are 3.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.69 - 2.7 | 2.7 - 2.72 |
| Low: | 2.24 - 2.25 | 2.25 - 2.26 |
| Close: | 2.51 - 2.53 | 2.53 - 2.55 |
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Thu, 04 Apr 2024
Aditxt, Inc. Announces Strategic Acquisition of Appili Therapeutics - TipRanks.com - TipRanks
Tue, 02 Apr 2024
Aditxt to acquire Appili Therapeutics in strategic move - Investing.com
Tue, 02 Apr 2024
Why Aditxt Stock Is Volatile Today - Aditxt (NASDAQ:ADTX) - Benzinga
Tue, 02 Apr 2024
Aditxt signs agreement to acquire Appili Therapeutics (NASDAQ:ADTX) - Seeking Alpha
Thu, 28 Mar 2024
Aditxt Inc (ADTX) Stock: What Does the Chart Say Thursday? - InvestorsObserver
Thu, 07 Mar 2024
Is it Time to Dump Aditxt Inc (ADTX) Stock After it Has Fallen 0.29% in a Week? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.64e+006 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.563e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 780 % |
| Return on Equity (ttm) | -59 % |
| Qtrly Rev. Growth | 645180 % |
| Gross Profit (p.s.) | -54.57 |
| Sales Per Share | -295.94 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -108.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.21 |
| Dividend | 0 |
| Forward Dividend | 19480 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|